Bio-Path Holdings Files S-1/A Amendment

TL;DR

BIO-PATH HOLDINGS (BPTH) filed an S-1/A amendment, looks like they're still working on registering shares.

AI Summary

Bio-Path Holdings, Inc. filed an S-1/A amendment on February 12, 2025, for its registration statement. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and is headquartered in Bellaire, Texas. This filing is an amendment to a previous registration statement, indicating ongoing efforts to register securities.

Why It Matters

This filing is a procedural step for Bio-Path Holdings, Inc. as they continue their process of registering securities with the SEC, which is crucial for potential future fundraising or stock offerings.

Risk Assessment

Risk Level: medium — S-1/A filings are typically related to securities registration, which can involve significant financial and regulatory risks for the company and investors.

Key Numbers

• 333-284363 — SEC File Number (Identifies the specific registration filing with the SEC.)

Key Players & Entities

• BIO-PATH HOLDINGS, INC. (company) — Registrant
• February 12, 2025 (date) — Filing Date
• 333-284363 (other) — SEC File Number
• Delaware (jurisdiction) — State of Incorporation
• Bellaire, Texas (location) — Principal Executive Offices
• Peter H. Nielsen (person) — President and Chief Executive Officer

FAQ

Key Financial Figures

• $0.001 — 1 shares of our common stock, par value $0.001 per share, together with (i) Series A w
• $0.769 — sumed combined public offering price of $0.769 per share and one Series A Warrant, one
• $0.125 — hare under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of common stock underly
• $0.768 — re and accompanying Common Warrants (or $0.768 per Pre-Funded Warrant TABLE OF CONTE

Filing Documents

• tm253664-3_s1a.htm (S-1/A) — 2162KB
• tm253664d4_ex4-24.htm (EX-4.24) — 105KB
• tm253664d4_ex4-25.htm (EX-4.25) — 111KB
• tm253664d4_ex4-26.htm (EX-4.26) — 112KB
• tm25366d4_ex4-27.htm (EX-4.27) — 102KB
• tm253664d4_ex4-28.htm (EX-4.28) — 111KB
• tm253664d4_ex5-1.htm (EX-5.1) — 17KB
• tm25366d4_ex10-41.htm (EX-10.41) — 220KB
• tm25366d4_ex23-1.htm (EX-23.1) — 2KB
• tm253664d4_ex-filingfees.htm (EX-FILING FEES) — 54KB
• lg_biopathholdings-4clr.jpg (GRAPHIC) — 15KB
• tb_statistics-4c.jpg (GRAPHIC) — 27KB
• tb_therapy-4c.jpg (GRAPHIC) — 34KB
• tb_refractory-4c.jpg (GRAPHIC) — 30KB
• bc_meanbodyweight-4clr.jpg (GRAPHIC) — 35KB
• tb_ovarian-4clr.jpg (GRAPHIC) — 17KB
• tb_endometrial-4clr.jpg (GRAPHIC) — 19KB
• tm253664d4_ex5-1img001.jpg (GRAPHIC) — 6KB
• tm253664d4_ex5-1img002.jpg (GRAPHIC) — 2KB
• 0001104659-25-011965.txt ( ) — 3251KB

RISK FACTORS

RISK FACTORS 11 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 43

USE OF PROCEEDS

USE OF PROCEEDS 45

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 48

BUSINESS

BUSINESS 61 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 82

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 88 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE 97

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 98

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 99

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 101 PLAN OF DISTRIBUTION 107 LEGAL MATTERS 110 EXPERTS 110 WHERE YOU CAN FIND MORE INFORMATION 110 i TABLE OF CONTENTS ABOUT THIS PROSPECTUS The registration statement we filed with the Securities and Exchange Commission (the "SEC") includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC before making your investment decision. You should rely only on the information provided in this prospectus. In addition, this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. This prospectus includes important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment decision. All of the summaries in this prospectus are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading "Where You Can Find More Information." We have not, and the Placement Agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we ha

View Full Filing

View this S-1/A filing on SEC EDGAR